As we explained in today’s Daily Briefing, the Brazilian Health Ministry announced a deal to purchase 20 million doses of Covaxin, the coronavirus vaccine developed by Indian lab Bharat Biotech. The agreement came as part of a strategy to boost vaccination efforts, which have suffered from a serious shortage of inputs and jabs, forcing several cities to momentarily suspend immunization campaigns. The Covaxin deal — valued at BRL 1.6 billion (USD 288 million) — will see doses arrive in Brazil between March and May.
However, according to government sources consulted by The Brazilian Report, there is more to the deal than meets the eye.
The Bharat Biotech purchase took many Health Ministry officials by surprise. Regulators have not signed off on Covaxin and the vaccine is not authorized for use or distribution in the...
Search
